Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children

MA Yi-Chen; ZHOU Xi-Hui; ZHAO Xiao-Dan; WANG Chen-Yang

doi:10.7499/j.issn.1008-8830.2406089

PDF(597 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (12) : 1294-1300. DOI: 10.7499/j.issn.1008-8830.2406089

CLINICAL RESEARCH

Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children

MA Yi-Chen, ZHOU Xi-Hui, ZHAO Xiao-Dan, WANG Chen-Yang

Author information +

History +

Abstract

Objective To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia (MUMPP) in children. Methods A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC. The efficacy and adverse drug reactions were compared between the two groups, and the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP) were analyzed. Results Compared with the PAZM group, the SDXC group had significantly shorter time to defervescence and time to cough relief, a significantly lower proportion of patients using glucocorticoids, and a significantly higher proportion of patients with lung lesion absorption (P<0.05). No adverse reactions such as liver and kidney function impairment and tooth discoloration were observed in either group. RMPP occurred in 47 cases in the PAZM group. The univariate analysis showed that lactate dehydrogenase levels and age were risk factors for RMPP (P<0.05). Conclusions The efficacy of SDXC is superior to that of PAZM in children with MUMPP, and short-term use of doxycycline is relatively safe.

Key words

Refractory Mycoplasma pneumoniae pneumonia / Azithromycin / Doxycycline / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

MA Yi-Chen, ZHOU Xi-Hui, ZHAO Xiao-Dan, WANG Chen-Yang. Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(12): 1294-1300 https://doi.org/10.7499/j.issn.1008-8830.2406089

References

1 Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond[J]. Clin Microbiol Rev, 2017, 30(3): 747-809. PMID: 28539503. PMCID: PMC5475226. DOI: 10.1128/CMR.00114-16.
2 Matsuda K, Narita M, Sera N, et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan[J]. BMC Infect Dis, 2013, 13: 591. PMID: 24330612. PMCID: PMC3883477. DOI: 10.1186/1471-2334-13-591.
3 Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children[J]. J Microbiol Immunol Infect, 2021, 54(4): 557-565. PMID: 33268306. DOI: 10.1016/j.jmii.2020.10.002.
4 Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae[J]. Front Microbiol, 2016, 7: 693. PMID: 27242718. PMCID: PMC4876131. DOI: 10.3389/fmicb.2016.00693.
5 Cardinale F, Chironna M, Chinellato I, et al. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children[J]. J Clin Microbiol, 2013, 51(2): 723-724. PMID: 23224091. PMCID: PMC3553869. DOI: 10.1128/JCM.02840-12.
6 赵顺英, 刘瀚旻, 陆权, 等. 儿童肺炎支原体肺炎诊治的专家释疑（2023年11月）[J]. 中华儿科杂志, 2024, 62(2): 108-113. PMID: 38228509. DOI: 10.3760/cma.j.cn112140-20231120-00382.
7 Hubert D, Dumke R, Weichert S, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae during an outbreak in a primary school: clinical characterization of hospitalized children[J]. Pathogens, 2021, 10(3): 328. PMID: 33802078. PMCID: PMC7999249. DOI: 10.3390/pathogens10030328.
8 中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南（2023年版）[J]. 国际流行病学传染病学杂志, 2023, 50(2): 79-85. DOI: 10.3760/cma.j.cn331340-20230217-00023.
9 曾兆彬, 王奇伟, 刘鼎立, 等. 不同剂量甲泼尼龙对小儿难治性肺炎支原体肺炎的疗效分析[J]. 中华全科医学, 2020, 18(7): 1150-1152, 1226. DOI: 10.16766/j.cnki.issn.1674-4152.001452.
10 Shah SS, Test M, Sheffler-Collins S, et al. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia[J]. J Hosp Med, 2012, 7(4): 311-317. PMID: 22271440. DOI: 10.1002/jhm.1904.
11 Ishiguro N, Koseki N, Kaiho M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients[J]. PLoS One, 2017, 12(3): e0173635. PMID: 28288170. PMCID: PMC5348022. DOI: 10.1371/journal.pone.0173635.
12 Chen J, Qi X, Yin Y, et al. Effects of minocycline on macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study[J]. Transl Pediatr, 2021, 10(11): 2997-3004. PMID: 34976765. PMCID: PMC8649588. DOI: 10.21037/tp-21-356.
13 Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients[J]. Antimicrob Agents Chemother, 2013, 57(5): 2252-2258. PMID: 23459497. PMCID: PMC3632908. DOI: 10.1128/AAC.00048-13.
14 Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth[J]. J Dent Res, 2005, 84(7): 596-602. PMID: 15972585. DOI: 10.1177/154405910508400703.
15 Chen Y, Zhang Y, Tang QN, et al. Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods[J]. Ital J Pediatr, 2024, 50(1): 38. PMID: 38439015. PMCID: PMC10913651. DOI: 10.1186/s13052-024-01615-y.
16 P?yh?nen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children[J]. J Antimicrob Chemother, 2017, 72(10): 2887-2890. PMID: 29091225. PMCID: PMC5890778. DOI: 10.1093/jac/dkx245.
17 Xie Q, Zhang X, Cui W, et al. Construction of a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia among macrolide-unresponsive mycoplasma pneumoniae pneumonia in children[J]. J Inflamm Res, 2022, 15: 6495-6504. PMID: 36474517. PMCID: PMC9719700. DOI: 10.2147/JIR.S387809.
18 郑雪香, 林继雷, 代继宏. 基于决策曲线和剂量反应分析评估乳酸脱氢酶对儿童难治性肺炎支原体肺炎的预测价值[J]. 中国当代儿科杂志, 2020, 22(2): 112-117. PMID: 32051076. PMCID: PMC7390016. DOI: 10.7499/j.issn.1008-8830.2020.02.006.
19 管峥, 霍洁, 袁晶, 等. 血清乳酸脱氢酶联合白细胞介素18对儿童难治性肺炎支原体肺炎的预测作用[J]. 实用医学杂志, 2020, 36(20): 2848-2851. DOI: 10.3969/j.issn.1006-5725.2020.20.021.
20 郭丽军. 小儿难治性肺炎支原体肺炎临床治疗分析[J]. 中国实用医药, 2011, 6(25): 68-69. DOI: 10.3969/j.issn.1673-7555.2011.25.046.
21 Ding G, Zhang X, Vinturache A, et al. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia[J]. Eur J Pediatr, 2024, 183(7): 3001-3011. PMID: 38634891. DOI: 10.1007/s00431-024-05519-1.